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Summary
Background Oesophageal adenocarcinoma represents one of the fastest rising cancers in high-income countries. 
Barrett’s oesophagus is the premalignant precursor of oesophageal adenocarcinoma. However, only a few patients 
with Barrett’s oesophagus develop adenocarcinoma, which complicates clinical management in the absence of valid 
predictors. Within an international consortium investigating the genetics of Barrett’s oesophagus and oesophageal 
adenocarcinoma, we aimed to identify novel genetic risk variants for the development of Barrett’s oesophagus and 
oesophageal adenocarcinoma.
Methods We did a meta-analysis of all genome-wide association studies of Barrett’s oesophagus and oesophageal 
adenocarcinoma available in PubMed up to Feb 29, 2016; all patients were of European ancestry and disease was 
conﬁ rmed histopathologically. All participants were from four separate studies within Europe, North America, and 
Australia and were genotyped on high-density single nucleotide polymorphism (SNP) arrays. Meta-analysis was done 
with a ﬁ xed-eﬀ ects inverse variance-weighting approach and with a standard genome-wide signiﬁ cance threshold 
(p<5 × 10–⁸). We also did an association analysis after reweighting of loci with an approach that investigates annotation 
enrichment among genome-wide signiﬁ cant loci. Furthermore, the entire dataset was analysed with bioinformatics 
approaches—including functional annotation databases and gene-based and pathway-based methods—to identify 
pathophysiologically relevant cellular mechanisms.
Findings Our sample comprised 6167 patients with Barrett’s oesophagus and 4112 individuals with oesophageal 
adenocarcinoma, in addition to 17 159 representative controls from four genome-wide association studies in Europe, 
North America, and Australia. We identiﬁ ed eight new risk loci associated with either Barrett’s oesophagus or 
oesophageal adenocarcinoma, within or near the genes CFTR (rs17451754; p=4·8 × 10–¹⁰), MSRA (rs17749155; 
p=5·2 × 10–¹⁰), LINC00208 and BLK (rs10108511; p=2·1 × 10–⁹), KHDRBS2 (rs62423175; p=3·0 × 10–⁹), TPPP and CEP72 
(rs9918259; p=3·2 × 10–⁹), TMOD1 (rs7852462; p=1·5 × 10–⁸), SATB2 (rs139606545; p=2·0 × 10–⁸), and HTR3C and 
ABCC5 (rs9823696; p=1·6 × 10–⁸). The locus identiﬁ ed near HTR3C and ABCC5 (rs9823696) was associated speciﬁ cally 
with oesophageal adenocarcinoma (p=1·6 × 10–⁸) and was independent of Barrett’s oesophagus development (p=0·45). 
A ninth novel risk locus was identiﬁ ed within the gene LPA (rs12207195; posterior probability 0·925) after reweighting 
with signiﬁ cantly enriched annotations. The strongest disease pathways identiﬁ ed (p<10–⁶) belonged to muscle cell 
diﬀ erentiation and to mesenchyme development and diﬀ erentiation.
Interpretation Our meta-analysis of genome-wide association studies doubled the number of known risk loci for 
Barrett’s oesophagus and oesophageal adenocarcinoma and revealed new insights into causes of these diseases. 
Furthermore, the speciﬁ c association between oesophageal adenocarcinoma and the locus near HTR3C and ABCC5 
might constitute a novel genetic marker for prediction of the transition from Barrett’s oesophagus to oesophageal 
adenocarcinoma. Fine-mapping and functional studies of new risk loci could lead to identiﬁ cation of key molecules 
in the development of Barrett’s oesophagus and oesophageal adenocarcinoma, which might encourage development 
of advanced prevention and intervention strategies.
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Introduction
Oesophageal adenocarcinoma is a fatal cancer that ranks 
eleventh in mortality among all malignant disorders.1 
Although new treatment strategies—eg, neoadjuvant 
chemoradiotherapy—have improved survival, patients 
with oesophageal adenocarcinoma still have a poor 
prognosis.2 Barrett’s oesophagus is the premalignant 
precursor of oesophageal adenocarcinoma and is 
characterised by a metaplastic change of the stratiﬁ ed 
squamous epithelium in the distal oesophagus to a 
glandular so-called intestinalised epithelium.3 The main 
risk factor for Barrett’s oesophagus is gastro-oesophageal 
reﬂ ux, whereby gastric acid chronically damages the 
epithelium of the distal oesophagus.3 However, although 
Barrett’s oesophagus has an estimated prevalence of up to 
5·6% in the population,4 only a few patients with this 
disorder—roughly 0·12% every year—develop oesophageal 
adenocarcinoma.5 This low progression rate complicates 
clinical management of Barrett’s oesophagus because no 
valid predictors for the transition from Barrett’s oesophagus 
to oesophageal adenocarcinoma exist, and thus there are 
no eﬀ ective surveillance and intervention strategies. 
Barrett’s oesophagus and oesophageal adenocarcinoma 
have heritable components with substantial overlap in 
the set of genes contributing to risk of each condition.6 
However, genetic risk factors contributing speciﬁ cally to 
Barrett’s oesophagus or oesophageal adenocarcinoma 
alone might also exist. So far, genome-wide association 
studies have identiﬁ ed four loci within or near MHC, 
FOXF1, GDF7, and TBX5 associated with the develop-
ment of Barrett’s oesophagus,7,8 and four additional loci 
within or near CRTC1, BARX1, FOXP1, and ALDH1A2 
associated with development of both Barrett’s oesophagus 
and oesophageal adenocarcinoma.8,9 However, because of 
small sample sizes analysed so far, these loci account for 
only a part of the genetic variance of Barrett’s oesophagus 
and oesophageal adeno carcinoma.6 Furthermore, these 
loci are insuﬃ  cient to predict the transition from 
Barrett’s oesophagus to oesophageal adenocarcinoma, 
because no speciﬁ c marker for oesophageal adeno-
carcinoma has been identiﬁ ed up to now.
Therefore, our international consortium aimed to do a 
meta-analysis of all available datasets from genome-wide 
association studies for Barrett’s oesophagus and 
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Research in context
Evidence before this study
We searched PubMed on Feb 29, 2016, to identify genetic risk 
markers for Barrett’s oesophagus and oesophageal 
adenocarcinoma identiﬁ ed through genome-wide association 
studies. We did not apply any publication date restrictions. 
The search was restricted to papers published in the English 
language. Search terms were: (“esophageal” OR “oesophageal” 
OR “esophagus” OR “oesophagus”) AND (“Barrett’s” OR 
“adenocarcinoma”) AND (“genome wide association study” OR 
“GWAS”). Three genome-wide association studies have been 
published to date and have led to the identiﬁ cation of eight 
genetic risk loci contributing to both Barrett’s oesophagus and 
oesophageal adenocarcinoma. These encouraging ﬁ ndings, 
however, account for only a part of the genetic risk for Barrett’s 
oesophagus and oesophageal adenocarcinoma. In particular, no 
variants have been identiﬁ ed so far that contribute solely to 
development of oesophageal adenocarcinoma and, thereby, 
might serve as markers for more eﬀ ective surveillance and 
intervention strategies for Barrett’s oesophagus.
Added value of this study
Within an international consortium, we did a meta-analysis of 
four datasets available to date from genome-wide association 
studies, totalling more than 27 000 individuals. We identiﬁ ed 
nine new risk loci for Barrett’s oesophagus or oesophageal 
adenocarcinoma, or both, which represents a doubling of the 
number of known risk loci. The most strongly associated new 
risk variant is located within CFTR, mutations of which lead to 
cystic ﬁ brosis. Patients with cystic ﬁ brosis show highly increased 
incidence of gastro-oesophageal reﬂ ux, and this reﬂ ux 
represents the main risk factor for Barrett’s oesophagus and 
oesophageal adenocarcinoma. Therefore, our data suggest that 
cystic ﬁ brosis, Barrett’s oesophagus, and oesophageal 
adenocarcinoma might have a common pathophysiological 
feature of gastro-oesophageal reﬂ ux, with CFTR playing an 
important part in this process. We also identiﬁ ed a risk variant 
near HTR3C/ABCC5 that was associated solely with development 
of oesophageal adenocarcinoma. This variant might constitute a 
novel marker for the prediction of transition from Barrett’s 
oesophagus to oesophageal adenocarcinoma.
Implications of all the available evidence
Identiﬁ cation of novel risk loci and cellular pathways provides 
further insights into the causes of Barrett’s oesophagus and 
oesophageal adenocarcinoma and impetus for further 
functional studies. The marker speciﬁ c to oesophageal 
adenocarcinoma should help to identify patients at higher risk 
for the transition from Barrett’s oesophagus to oesophageal 
adenocarcinoma. Together, this information should lead to 
better molecular treatments and individualised prevention and 
intervention strategies for clinical management of Barrett’s 
oesophagus and oesophageal adenocarcinoma.
Articles
www.thelancet.com/oncology   Published online August 12, 2016   http://dx.doi.org/10.1016/S1470-2045(16)30240-6 3
Interventional Endoscopy, 
St John of God Hospital, 
Regensburg, Germany 
(O Pech MD); Department of 
Visceral Surgery, Kantonsspital 
Aarau AG, Aarau, Switzerland 
(Y Vashist); Department of 
General, Visceral and Thorax 
Surgery, RoMed Klinikum 
Rosenheim, Rosenheim, 
Germany (K Ott); 
Gastroenterologische 
Gemeinschaftspraxis, Koblenz, 
Germany (J Weismüller MD); 
Centre For Integrated Health 
Care Research, Durham 
University, Durham, UK 
(S Attwood MD); Gloucestershire 
Royal Hospital, Gloucester, UK 
(H Barr MD); Plymouth 
University Peninsula School of 
Medicine and Dentistry, 
Plymouth, UK 
(L Chegwidden MSc); Digestive 
Diseases Centre, University 
Hospitals of Leicester, Leicester, 
UK (J de Caestecker MD); 
Department of Cellular 
Pathology, Leicester Royal 
Infirmary, Leicester, UK 
(R Harrison MD); Department of 
Oral Biological and Medical 
Sciences, University of British 
Columbia, Vancouver, BC, 
Canada (D MacDonald DDS); 
Department of Medicine, 
McMaster University, Hamilton, 
ON, Canada (P Moayyedi MD); 
Department of 
Gastroenterology, University 
Hospitals Gasthuisberg, Leuven, 
Belgium (H Prenen MD); Queen’s 
University Belfast, Centre of 
Medical Education, Royal 
Victoria Hospital, Belfast, UK 
(R G P Watson MD); Division of 
Gastroenterology and 
Hepatology, Department of 
Internal Medicine, Mayo Clinic, 
Rochester, MN, USA 
(P G Iyer MD); Centre for Public 
Health, Queen’s University 
Belfast, Belfast, UK 
(L A Anderson PhD); Department 
of Population Sciences, 
Beckman Research Institute and 
City of Hope Comprehensive 
Cancer Center, Duarte, CA, USA 
(L Bernstein PhD); Department 
of Epidemiology, MD Anderson 
Cancer Center, Houston, TX, 
USA (W-H Chow PhD); Division 
of Epidemiology, University of 
Leeds, Leeds, UK (L J Hardie PhD); 
Department of Molecular 
Medicine and Surgery 
(Prof J Lagergren PhD), and 
Department of Medical 
Epidemiology and Biostatistics 
(Prof W Ye PhD), Karolinska 
Institute, Stockholm, Sweden; 
oesophageal adenocarcinoma to identify additional 
genetic variants associated with risk for both disorders. 
Furthermore, we aimed to identify genetic variants 
that contribute speciﬁ cally to risk for oesophageal 
adenocarcinoma and, thereby, might serve as markers for 
individualised surveillance and intervention strategies for 
Barrett’s oesophagus. To our knowledge, our study is the 
ﬁ rst in which datasets from genome-wide association 
studies have been analysed using bioinformatics 
approaches to gain further information about the 
underlying genes and cellular pathways associated with 
Barrett’s oesophagus and oesophageal adenocarcinoma. 
Methods
Study design and participants
We obtained genome-wide genotype data for patients 
with Barrett’s oesophagus, individuals with oesophageal 
adenocarcinoma, and representative controls from 
four genome-wide association studies in Europe, North 
America, and Australia:7–9 the Barrett’s and Esophageal 
Adenocarcinoma Consortium (BEACON) study; and 
studies from Bonn, Cambridge, and Oxford (appendix 
pp 5–6, 11). Data from the Bonn study are unpublished; 
the Oxford study did not contribute data for patients 
with oesophageal adenocarcinoma. All participants were 
of European ancestry, and DNA samples extracted from 
blood or saliva were genotyped on high-density single 
nucleotide polymorphism (SNP) arrays (Illumina, 
San Diego, CA, USA). 
Patients with Barrett’s oesophagus were identiﬁ ed by 
histopathological diagnosis of intestinal metaplasia, and 
individuals with oesophageal adenocarcinoma had a 
histopathological diagnosis of adenocarcinoma. We 
excluded all other patients. Informed consent was 
obtained in the four studies from all participants and 
ethics approval was obtained from the ethics boards of 
every participating institution. 
Procedures
We did a quality control assessment of genotyped 
markers, genotyped individuals, and the imputation, 
using the same protocol at all participating sites. We used 
PLINK version 1.9010 for quality control. We removed all 
individuals with more than 3% of missing genotypes; 
SNPs with a successful genotyping rate of less than 97%; 
SNPs with a minor allele frequency less than 0·01; SNPs 
with a p value of less than 0·0001 in controls and less 
than 5 × 10−¹⁰ in patients for Hardy-Weinberg equilibrium; 
and SNPs with a signiﬁ cant (p<0·001) diﬀ erence in 
missingness between cases and controls. Based on 
identity by descent calculated from autosomal markers, 
we removed one of each pair of individuals with high 
levels of relatedness (p-hat>0·2) and a higher proportion 
of missing genotypes. We also removed participants who 
lay beyond six SDs from the mean of the ﬁ rst two 
genotypic principal components of the 1000 Genomes 
European descent population.11
For the imputation, we used SHAPEIT version 2.1212 
for phasing of the genotyped SNPs and IMPUTE2 
version 2.3.113,14 for imputation of missing SNPs, using 
the 1000 Genomes Phase 1 haplotypes (June, 2014 release) 
as a reference panel.15 We did the imputation in 5 Mb 
sections. We set a 250 kb buﬀ er ﬂ anking the imputation 
sections and an eﬀ ective size of the sampled population 
of 20 000, as recommended for IMPUTE2 version 2.3.1.13,14
Statistical analysis
We did association testing for Barrett’s oesophagus and 
oesophageal adenocarcinoma as separate disorders. We 
then repeated the analysis after combining the two groups 
of patients into a single group. We assessed associations in 
SNPTEST version 2.5.2,16 adjusted for sex and study-speciﬁ c 
top principal components, under an additive genetic 
model using dosage scores (based on the probabilities for 
each of the three possible genotypes of every SNP) obtained 
from the imputation. Dosage scores account for imputation 
uncertainty in the association analysis, by contrast with the 
best-guess approach, whereby the most probable genotype 
of every SNP obtained from imputation is regarded as the 
actual genotype for that SNP. We calculated the genomic 
inﬂ ation factor lambda (λ) to ensure that the results were 
not aﬀ ected by model mis-speciﬁ cation. A high inﬂ ation 
factor might indicate presence of population stratiﬁ cation, 
unknown familial relationships, undetected sample 
duplications, technical problems with the data, or 
application of incorrect statistical methods.
We analysed SNPs that passed the post-imputation 
quality control assessment in every study (imputation 
quality score >0·4, minor allele frequency >0·001) and 
were present in at least three studies of Barrett’s 
oesophagus and two studies of oesophageal adeno-
carcinoma. An imputation quality score greater than 0·4 
ensures that SNPs that were not well imputed were 
excluded, and a minor allele frequency greater than 
0·001 ensures that SNPs that were not common in our 
study population were excluded from the analysis 
(appendix pp 5–6). We did the meta-analysis with the 
ﬁ xed-eﬀ ects inverse variance-weighting approach in 
METAL version 2011-03-25,17 with a standard genome-
wide signiﬁ cant threshold of 5 × 10–⁸.
We investigated the presence of genetic heterogeneity 
between studies with the I² statistic, and we calculated 
p values for heterogeneity with Cochran’s Q test, as 
implemented in METAL version 2011-03-25.17 Presence of 
genetic heterogeneity indicates that eﬀ ect sizes are not 
similar between studies, emphasising the possibility of a 
distribution of true eﬀ ect sizes between studies. 
Random-eﬀ ects meta-analysis deals with this situation 
by decomposing the observed variance into its 
two components, within and between study variance, 
and uses both components for weighting. We did 
random-eﬀ ects meta-analysis in PLINK version 1.9010 for 
all genome-wide signiﬁ cant SNPs that showed signiﬁ cant 
genetic heterogeneity (p for heterogeneity <0·05).
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We created Q-Q and Manhattan plots for the 
meta-analysis in R. We used LocusZoom version 1.118 to 
create regional association plots for genome-wide 
signiﬁ cant results. 
To investigate whether independent associations 
exist in regions of genome-wide signiﬁ cance, we did 
association analyses conditioned on the strongest 
associated SNP in every region (1 Mb either side of the 
top SNPs) with meta-analysis summary statistics and 
the approach implemented in GCTA version 1.25.2.19 
This approach uses both summary-level statistics from 
genome-wide association studies and estimated linkage 
disequilibrium from a reference sample (the imputed 
BEACON data in this study) to investigate whether 
single or multiple independent associations exist for 
every locus. 
Because some SNPs could be associated with Barrett’s 
oesophagus and oesophageal adenocarcinoma but not 
meet the genome-wide signiﬁ cance threshold because 
of insuﬃ  cient statistical power (ie, SNPs with small 
eﬀ ect sizes cannot be detected in our current sample 
size using stringent criteria for signiﬁ cance), we used a 
new approach20 in which functional annotation 
information from genome-wide signiﬁ cant loci is used 
to reweight the results. Incorporating functional 
annotation information to reweight data from genome-
wide association studies could result in identiﬁ cation of 
new risk loci that otherwise might not reach the 
genome-wide signiﬁ cance threshold in standard 
genome-wide association studies. This approach, which 
is implemented in fgwas version 1.0,20 is capable 
of identifying additional high-conﬁ dence risk loci, 
resulting in a roughly 5% increase in the number of 
identiﬁ ed loci when tested on previously published data 
from genome-wide association studies.20 We looked at 
enrichment of 450 genomic annotations as implemented 
in fgwas version 1.020 (default settings: 5000 SNPs 
per window). We derived the best annotations from 
genome-wide signiﬁ cant loci in the Barrett’s oesophagus 
and oesophageal adenocarcinoma combined analysis. 
We ﬁ rst considered annotations separately to see if they 
were individually signiﬁ cant. Some annotations were 
correlated and, hence, we built a model by adding terms 
sequentially in decreasing order of signiﬁ cance until no 
more annotations signiﬁ cantly (p<0·05) improved 
the log-likelihood of the model. We then applied 
the cross-validation approach implemented in fgwas 
version 1.0 to ensure no over-ﬁ tting in the ﬁ nal model. 
We used this ﬁ nal Bayesian model to derive a prior 
distribution for the remainder of the genome. We 
calculated the posterior probability of association based 
on the derived prior distribution. A posterior probability 
greater than 0·9 in this approach performed 
similarly to the genome-wide signiﬁ cance threshold in 
genome-wide association studies (p<5 × 10–⁸) based 
on the analysis20 of previously published genome-wide 
association studies.20
We did gene-based association tests with the approach 
implemented in VEGAS version 2,21 a simulation-based 
approach that combines the test statistics for single 
variants within gene boundaries while accounting for 
linkage disequilibrium between markers. We set the 
Bonferroni-corrected threshold for gene-wide signi-
ﬁ cance to a p value of less than 2·8 × 10−⁶ (considering 
17 787 autosomal genes used in VEGAS version 2).
We analysed pathways and tissue enrichment with 
methods implemented in DEPICT version 1.1.22 The 
preference is to use genome-wide signiﬁ cant SNPs as 
long as at least ten independent loci are available. 
However, because of the polygenic basis of complex 
traits, restricting the pathways analysis to only genome-
wide signiﬁ cant SNPs might result in some informative 
data being missed. This omission is because many SNPs 
that do not meet the genome-wide signiﬁ cance threshold 
might still be associated with either Barrett’s oesophagus 
or oesophageal adenocarcinoma (or both), but might not 
be detected because of insuﬃ  cient statistical power. 
Accordingly, we included loci from the combined 
Barrett’s oesophagus and oesophageal adenocarcinoma 
meta-analysis that achieved one of three p value 
thresholds (p<5 × 10–⁸, p<10–⁶, and p<10–⁴) for pathways 
analysis. We set the Bonferroni-corrected threshold for 
pathways analysis at a p value of less than 1·15 × 10–⁶ 
(considering multiple testing with the three p-value 
thresholds and assuming all 14 463 pathways used in 
DEPICT version 1.1 are independent) and a false discovery 
rate of less than 0·05. Similarly, we set the Bonferroni-
corrected threshold for tissue-enrichment analysis to a 
p value of less than 8 × 10–⁵ (considering multiple testing 
with the three p-value thresholds and assuming that 
gene expression in all 209 tissue and cell samples used in 
DEPICT version 1.1 is independent) and a false discovery 
rate less than 0·05. 
We did bioinformatics analyses as described in the 
appendix (p 6). We investigated whether published risk 
loci for gastro-oesophageal reﬂ ux-predisposing traits 
(eg, body-mass index [BMI] and obesity), which have 
shown genome-wide signiﬁ cant associations,23 represent 
risk loci for Barrett’s oesophagus and oesophageal 
adeno carcinoma. We also estimated the peak SNPs 
identiﬁ ed in this study in the genome-wide association 
analysis for BMI undertaken by the Genetic Investigation 
of ANthropometric Traits (GIANT) consortium.24 
Additional details of methods used for functional 
annotation enrichment analysis, gene-based analysis, 
and tissue enrichment analysis are in the appendix (p 7).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study, except personal identifying information, and 
had ﬁ nal responsibility for the decision to submit for 
publication. 
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Results
6167 people with Barrett’s oesophagus, 4112 individuals 
with oesophageal adenocarcinoma, and 17 159 represen-
tative controls from four genome-wide association 
studies in Europe, North America, and Australia were 
included in the meta-analysis. In total, 11 942 825 SNPs 
for Barrett’s oesophagus, 13 074 274 for oesophageal 
adenocarcinoma, and 11 951 684 for both Barrett’s 
oesophagus and oesophageal adenocarcinoma were 
used for the meta-analysis of genome-wide association 
studies. Q-Q and Manhattan plots from the separate 
Barrett’s oesophagus and oesophageal adenocarcinoma 
meta-analyses, and from the combined Barrett’s 
oesophagus and oesophageal adenocarcinoma meta-
analysis, are shown in the appendix (pp 8–9). The scaled 
genomic inﬂ ation factor lambda (λ) was 1·043 for the 
Barrett’s oesophagus meta-analysis, 1·005 for the 
oesophageal adenocarcinoma meta-analysis, and 1·049 
for the combined Barrett’s oesophagus and oesophageal 
adenocarcinoma meta-analysis. 
Five genome-wide signiﬁ cant associated loci (p<5 × 10–⁸) 
were identiﬁ ed for Barrett’s oesophagus alone, of which 
three were not previously reported (appendix p 11). 
Moreover, ﬁ ve genome-wide signiﬁ cant associated loci 
(p<5 × 10–⁸) for oesophageal adeno carcinoma alone were 
identiﬁ ed, of which four were previously unreported 
(appendix p 12). The combined meta-analysis for Barrett’s 
oesophagus and oesophageal adenocarcinoma identiﬁ ed 
14 genome-wide signiﬁ cant associated loci (p<5 × 10–⁸), of 
which seven were previously unreported (table). Of note, 
all seven new genome-wide signiﬁ cant loci from 
the separate Barrett’s oesophagus and oesophageal 
adenocarcinoma meta-analyses were also identiﬁ ed in the 
combined meta-analysis except for one locus on 
chromosome 3q27 near HTR3C and ABCC5 (rs9823696) 
that was only recorded in the oesophageal adenocarcinoma 
meta-analysis and, therefore, was speciﬁ c for this disorder 
(risk for oesophageal adenocarcinoma: odds ratio [OR] 
1·17, 95% CI 1·11–1·24; p=1·64 × 10–⁸; risk for Barrett’s 
oesophagus: 1·02, 0·97–1·06; p=0·45). By contrast, all risk 
loci identiﬁ ed for Barrett’s oesophagus were also 
associated with oesophageal adenocarcinoma (at least 
p<0·02; appendix p 13). 
Regional association results for all novel Barrett’s 
oesophagus and oesophageal adenocarcinoma loci are 
shown in ﬁ gure 1. The most strongly associated SNPs 
were rs17451754 on chromosome 7q31 within CFTR 
(p=4·77 × 10–¹⁰; ﬁ gure 1A), rs17749155 on chromosome 
8p23 within MSRA (p=5·21 × 10–¹⁰; ﬁ gure 1B), rs10108511 
on chromosome 8p23 within LINC00208 and BLK 
(p=2·12 × 10–⁹; ﬁ gure 1C), rs62423175 on chromosome 
6q11 near KHDRBS2 and MTRNR2L9 (p=2·95 × 10–⁹; 
ﬁ gure 1D), rs9918259 on chromosome 5p15 within TPPP 
and CEP72 (p=3·23 × 10–⁹; ﬁ gure 1E), rs7852462 on 
chromosome 9q22 within TMOD1 (p=1·49 × 10–⁸; 
ﬁ gure 1F), and rs139606545 on chromosome 2q33 near 
SATB2 (p=2·02 × 10–⁸; ﬁ gure 1G). We identiﬁ ed an 
additional risk locus for Barrett’s oesophagus and 
oesophageal adenocarcinoma (rs12207195) at the gene 
LPA on chromosome 6q26 (ﬁ gure 1H). Although 
rs12207195 did not reach genome-wide signiﬁ cance in the 
frequentist analysis (p=2·1 × 10–⁷), the posterior probability 
for the region containing LPA was 0·925 in the empirical 
Bayesian approach (compared with 0·863 without 
weighting by annotation; appendix p 7), corresponding to 
p<5 × 10–⁸ in the frequentist inference. The appendix (p 13) 
shows the association results of the top associated SNPs 
from the combined meta-analysis in the separate Barrett’s 
oesophagus and oesophageal adenocarcinoma analyses. 
Figure 2 shows regional association results for 
the oesophageal adenocarcinoma-speciﬁ c locus near 
HTR3C and ABCC5 (rs9823696) in oesophageal 
Chromosome Position* Tested allele Other allele Nearest gene or region INFO score† Odds ratio (95% CI) p p for heterogeneity
rs7255 2 20878820 T C GDF7 and LDAH 0·92 1·14 (1·09–1·18) 9·1 × 10–¹¹ 0·78
rs2464469 15 58362025 A G ALDH1A2 0·97 0·89 (0·85–0·92) 4·6 × 10–¹⁰ 0·19
rs17451754‡ 7 117256712 A G CFTR 0·97 0·84 (0·80–0·89) 4·8 × 10–¹⁰ 0·61
rs17749155‡ 8 10068073 A G MSRA 0·91 1·18 (1·12–1·24) 5·2 × 10–¹⁰ 0·77
rs10108511‡ 8 11435516 T C LINC00208 and BLK 0·98 1·12 (1·08–1·16) 2·1 × 10–⁹ 0·84
rs2687202 3 70929983 T C FOXP1 0·99 1·13 (1·08–1·17) 2·3 × 10–⁹ 0·92
rs1247942 12 114673723 C G LOC105369996 and TBX5 0·98 0·89 (0·86–0·92) 2·3 × 10–⁹ 0·91
rs62423175‡ 6 62195368 A G KHDRBS2 and MTRNR2L9 0·87 1·17 (1·11–1·23) 3·0 × 10–⁹ 0·29
rs9918259‡ 5 663092 T C TPPP and CEP72 0·56 1·20 (1·13–1·27) 3·2 × 10–⁹ 0·037
rs9257809 6 29356331 A G MHC region 0·91 1·23 (1·14–1·31) 5·9 × 10–⁹ 0·35
rs7852462‡ 9 100310501 T C TMOD1 0·94 0·89 (0·86–0·93) 1·5 × 10–⁸ 0·54
rs139606545‡ 2 200045039 T C SATB2 0·98 0·90 (0·86–0·93) 2·0 × 10–⁸ 0·27
rs1979654 16 86396835 C G LOC732275 and FOXF1 0·97 0·90 (0·86–0·93) 3·3 × 10–⁸ 0·29
rs199620551 19 18804294 T TG CRTC1 0·96 0·90 (0·87–0·93) 4·7 × 10–⁸ 0·68
SNP=single nucleotide polymorphism. *Position in Genome Reference Consortium human genome (build 37). †Average of imputation quality score (INFO score) between cohorts. ‡New risk variants at 
genome-wide signiﬁ cance level (p<5 × 10–⁸).
Table: Top SNPs from loci meeting the threshold for genome-wide signiﬁ cance in the combined Barrett’s oesophagus and oesophageal adenocarcinoma meta-analysis 
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Figure 1: Regional plots for 
loci meeting the threshold 
for genome-wide 
signiﬁ cance in both Barrett’s 
oesophagus and oesophageal 
adenocarcinoma
Regional associations for the 
most signiﬁ cantly associated 
single nucleotide 
polymorphisms (SNPs; marked 
as solid purple diamonds) in 
the combined Barrett’s 
oesophagus and oesophageal 
adenocarcinoma 
meta-analysis (includes 
10 279 patients with Barrett’s 
oesophagus and oesophageal 
adenocarcinoma and 
17 159 controls). Pairwise 
correlations (r²) between the 
top SNP and the other SNPs in 
a 400 kb ﬂ anking region are 
illustrated by diﬀ erent colours. 
Grey dots denote the SNPs 
that were not present in the 
reference panel that was used 
to calculate linkage 
disequilibrium between SNPs. 
Light orange spikes show 
estimated recombination 
rates. (A) rs17451754 
on chromosome 7q31 within 
CFTR. (B) rs17749155 on 
chromosome 8p23 within 
MSRA. (C) rs10108511 on 
chromosome 8p23 within 
LINC00208 and BLK. 
(D) rs62423175 on 
chromosome 6q11 near 
KHDRBS2 and MTRNR2L9. 
(E) rs9918259 on 
chromosome 5p15 within 
TPPP and CEP72. 
(F) rs7852462 on 
chromosome 9q22 within 
TMOD1. (G) rs139606545 on 
chromosome 2q33 near 
SATB2. (H) rs12207195 on 
chromosome 6q26 within 
LPA. cM=centimorgan.
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adenocarcinoma and in Barrett’s oesophagus. Although 
we did not identify any secondary peaks (ie, associations 
of SNPs with oesophageal adenocarcinoma and Barrett’s 
oesophagus that were independent of the top hits) at 
genome-wide signiﬁ cance in the conditional association 
analysis of the combined meta-analysis, two loci 
(rs34817486 near FOXF1-AS1 [also known as FENDRR] 
and FOXF1, and rs62331139 near LPCAT1 and SLC6A3) 
showed some evidence of secondary peaks (p<10–⁵; 
appendix p 10).
Of the nine newly identiﬁ ed risk loci, only SNPs within 
or near TPPP and CEP72 showed signiﬁ cant (p<0·05) 
heterogeneity for the magnitudes of association of SNPs 
between studies in the ﬁ xed-eﬀ ects meta-analysis 
(heterogeneity I²=64·5 and p=0·0375 for rs9918259, the 
most signiﬁ cantly associated SNP at this locus; table). All 
studies in this meta-analysis showed the same direction 
of eﬀ ect for risk alleles at this locus. However, the 
magnitude of association was larger in the Bonn study 
compared with the other studies—ie, the Bonn study OR 
was 1·43 (95% CI 1·25–1·64) for the risk allele of 
rs9918259, whereas it was 1·18 (1·08–1·29) in the 
BEACON study, 1·11 (0·98–2·49) in the Cambridge 
study, and 1·12 (0·99–1·28) in the Oxford study. Under a 
random-eﬀ ects model, the SNP rs9918259 was less 
signiﬁ cantly associated with Barrett’s oesophagus 
and oesophageal adenocarcinoma in the combined 
meta-analysis (p=4·7 × 10–⁴) than with the ﬁ xed eﬀ ects 
meta-analysis (p=3·2 × 10–⁹). Consistent with p values for 
heterogeneity for the other risk loci (table), the magnitude 
and direction of eﬀ ect were consistent between all studies 
for the remaining risk loci. Thus, we did not do a 
random-eﬀ ects meta-analysis for these loci.
All previously reported genome-wide signiﬁ cant 
loci7–9—including GDF7, ALDH1A2, TBX5, CRTC1, 
FOXP1, FOXF1, and the MHC region (table)—were also 
associated with both Barrett’s oesophagus and 
oesophageal adenocarcinoma at the genome-wide 
signiﬁ cance threshold. Only the BARX1 locus9 did not 
meet the genome-wide signiﬁ cance threshold, but it still 
showed strong association with Barrett’s oesophagus 
and oesophageal adenocarcinoma in the combined 
meta-analysis (p=6·2 × 10–⁷ for rs11789015). Apart from 
the risk loci identiﬁ ed in the single variant analysis, we 
did not identify other loci reaching gene-based 
genome-wide signiﬁ cance (p<2·8 × 10–⁶) after correction 
for genomic inﬂ ation in the gene-based association 
analysis (appendix p 7). 
In the pathway analyses, no pathways were 
signiﬁ cantly associated with Barrett’s oesophagus 
and oesophageal adenocarcinoma at the thresholds 
p<1·15 × 10–⁶ and false discovery rate <0·05 using SNPs 
satisfying p<5 × 10–⁸ and p<10–⁶ in the combined 
meta-analysis. However, for SNPs satisfying p<1 × 10–⁴ 
in the combined meta-analysis, four pathways were 
signiﬁ cantly associated with Barrett’s oesophagus and 
oesophageal adenocarcinoma (appendix p 14): negative 
regulation of muscle-cell diﬀ erentiation (GO:0051148); 
mesenchyme development (GO:0060485); BMPR2 PPI 
subnetwork (ENSG00000204217); and mesenchymal 
cell diﬀ erentiation (GO:0048762). Separate Barrett’s 
oesophagus and oesophageal adeno carcinoma pathways 
analyses with these thresholds did not identify any 
signiﬁ cant pathway. In tissue enrichment analyses, 
genes within the combined Barrett’s oesophagus and 
Figure 2: Regional plots for the oesophageal adenocarcinoma-speciﬁ c locus rs9823696 near HTR3C and ABCC5 
Regional associations for the most signiﬁ cantly associated single nucleotide polymorphism (SNP; marked as a solid 
purple diamond), rs9823696, in the oesophageal adenocarcinoma meta-analysis. Pairwise correlations (r²) between 
the top SNP and the other SNPs in a 400 kb ﬂ anking region are illustrated by diﬀ erent colours. Grey dots denote the 
SNPs that were not present in the reference panel that was used to calculate linkage disequilibrium between SNPs. 
Light orange spikes show estimated recombination rates. (A) Genome-wide signiﬁ cance in 4112 patients with 
oesophageal adenocarcinoma and 13 663 controls (p=1·64 × 10–⁸). (B) Not signiﬁ cant in 6167 patients with 
Barrett’s oesophagus and 17 159 controls (p=0·45). cM=centimorgan. 
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oesophageal adenocarcinoma associated regions were 
highly expressed in the digestive system, as well as in 
the endocrine system, cardiovascular system, and in 
smooth muscle (appendix pp 7, 15). 
None of the published genome-wide signiﬁ cant risk loci 
for BMI and obesity were associated with Barrett’s 
oesophagus and oesophageal adenocarcinoma in the 
combined meta-analysis at the genome-wide signiﬁ cance 
level (data not shown). However, rs2898290 (within 
LINC00208 and BLK), which is strongly associated with 
Barrett’s oesophagus and oesophageal adenocarcinoma 
(p=1·2 × 10–⁸), showed some evidence of association with 
BMI in the GIANT study24 (p=0·001058).
The nine newly identiﬁ ed Barrett’s oesophagus and 
oesophageal adenocarcinoma risk loci were characterised 
by analysis of multiple functional annotation databases 
(appendix pp 16–18). Many loci harbour genes expressed 
in the gastrointestinal tract and that have a role in 
oncogenesis. Furthermore, some of the identiﬁ ed risk 
variants—or variants that are highly correlated with them 
(r²>0·80)—represent expression quantitative trait loci 
that regulate the expression of genes within the regions. 
Moreover, several of the implicated risk variants change 
sequence motifs for protein binding sites and are located 
within DNAase hypersensitivity regions and within 
regions with enhancer or promoter motifs.
Discussion
Our meta-analysis identiﬁ ed 16 independent risk loci 
for development of Barrett’s oesophagus, oesophageal 
adenocarcinoma, or both, at the level of genome-wide 
signiﬁ cance. Nine loci had not been identiﬁ ed before; all 
previously reported risk loci were associated with both 
Barrett’s oesophagus and oesophageal adenocarcinoma 
in our meta-analysis. Thus, our study has more than 
doubled the number of known risk loci for Barrett’s 
oesophagus and oesophageal adenocarcinoma, which 
further exempliﬁ es the scientiﬁ c value of meta-analysis 
of genome-wide association studies through international 
collaborations. Moreover, we identiﬁ ed an oesophageal 
adenocarcinoma-speciﬁ c risk locus that was independent 
of development of Barrett’s oesophagus. The sample size 
of our meta-analysis was large enough to do a pathway 
analysis to investigate genetic pathways associated with 
development of Barrett’s oesophagus and oesophageal 
adenocarcinoma. Our ﬁ ndings indicated that cellular 
pathways involved in muscle-cell diﬀ erentiation and 
mesenchyme development and diﬀ erentiation were 
implicated in causing Barrett’s oesophagus and 
oesophageal adenocarcinoma. 
Findings of the functional annotation database analysis 
of the newly identiﬁ ed Barrett’s oesophagus and 
oesophageal adenocarcinoma risk loci exemplify how 
data from genome-wide association studies can uncover 
new causal and clinical aspects of Barrett’s oesophagus 
and oesophageal adenocarcinoma (appendix pp 18–19). 
The newly identiﬁ ed risk locus with the strongest 
association with Barrett’s oesophagus and oesophageal 
adenocarcinoma (p=4·8 × 10–¹⁰) was rs17451754 on 
chromosome 7q31. This SNP is located within intron 21 
of the CFTR gene and aﬀ ects a region marked by 
enhancer histone modiﬁ cations in the gastrointestinal 
tract mucosa and by DNAse hypersensitivity.25 CFTR 
encodes an ATP-binding cassette membrane protein that 
functions as a chloride channel and is mutated in cystic 
ﬁ brosis,26 the most common autosomal recessive disorder 
among people of European ancestry. Mutations in CFTR 
lead to secretions that are abnormally viscous and 
altered in their chemical composition, leading to severe 
dysfunction of the respiratory system and gastrointestinal 
tract. Up to 81% of patients with cystic ﬁ brosis have 
gastro-oesophageal reﬂ ux, a major risk factor for Barrett’s 
oesophagus and oesophageal adenocarcinoma, and 
more than 50% of these individuals are treated with 
proton-pump inhibitors in high-income countries.27 
According to ﬁ ndings of a 20-year nationwide survey 
from the USA,28 incidence of cancer at the gastro-
oesophageal junction is also increased among patients 
with cystic ﬁ brosis, with evidence of Barrett’s oesophagus 
in these patients. Although the cause of gastro-oesophageal 
reﬂ ux seems to diﬀ er between most patients with and 
without cystic ﬁ brosis, the exact mechanism of reﬂ ux 
in patients with cystic ﬁ brosis is still not understood 
fully. Favoured pathophysiological ideas about gastro-
oesophageal reﬂ ux in patients with cystic ﬁ brosis include 
lower inspiratory intrathoracic pressure with altered 
gastro-oesophageal pressure gradients,29 delayed gastric 
emptying,30 and impaired neutralisation of reﬂ ux-acidiﬁ ed 
oesophageal mucosa because of reduced bicarbonate 
secretion or hyperacidity of reﬂ uxed gastric contents.31 
However, in view of the phenotypic overlap for 
gastro-oesophageal reﬂ ux and cystic ﬁ brosis, and for 
gastro-oesophageal reﬂ ux and both Barrett’s oesophagus 
and oesophageal adeno carcinoma, combined with the 
identiﬁ cation of CFTR risk variants in patients with 
Barrett’s oesophagus and oesophageal adenocarcinoma, 
it seems plausible that a common pathophysiological 
mechanism for gastro-oesophageal reﬂ ux is triggered by 
CFTR. This idea underlines the importance of CFTR as a 
true disease gene within this region. Fine mapping of all 
genetic variation at this locus, and extensive functional 
studies, are needed to test this hypothesis because other 
pathomechanisms and risk genes cannot be excluded 
entirely. Moreover, detailed genotype–phenotype studies 
of Barrett’s oesophagus and oeso phageal adenocarcinoma, 
and of isolated patients with gastro-oesophageal reﬂ ux 
stratiﬁ ed for the CFTR risk variant, are needed that take 
the implicated mechanisms of gastro-oesophageal reﬂ ux 
in cystic ﬁ brosis into account. This work might yield 
new insights in the area of Barrett’s oesophagus and 
oesophageal adenocarcinoma research.
To our knowledge, the ﬁ rst risk locus to be identiﬁ ed 
that is speciﬁ c to oesophageal adenocarcinoma is 
rs9823696 on chromosome 3q27. This SNP lies 4·9 kb 
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downstream of the HTR3C gene. Highly correlated 
variants of this marker (r²>0·80) have been identiﬁ ed as 
regulatory active expression quantitative trait loci that 
aﬀ ect expression of the ABCC5 gene at this locus.32 
However, these regulatory eﬀ ects were studied in blood 
cells32 and, thus, further work needs to be done to ﬁ nd 
out if these expression quantitative trait loci are also 
present in tissues relevant to oesophageal adeno-
carcinoma. However, on the functional level, ABCC5 
represents an interesting oesophageal adenocarcinoma 
candidate gene. The corresponding gene product belongs 
to the group of ATP-binding cassette membrane proteins 
that play a part in energy-dependent transport of various 
endogenous and exo genous substrates and has been 
implicated in cancer development and progression.33,34 
Furthermore, as with other oesophageal adenocarcinoma 
genes implicated by genome-wide association studies 
(eg, FOXF1 and FOXP1),7,9 ABCC5 has a role during 
embryonal develop ment of the intestine.35 Apart from 
the exact functional role of rs9823696, markers that 
contribute solely to oesophageal adenocarcinoma 
development could serve as predictors for disease 
progression in Barrett’s oesophagus. Because Barrett’s 
oesophagus is common in the population and only a few 
patients develop oesophageal adenocarcinoma, speciﬁ c 
markers for the transition of Barrett’s oesophagus to 
oesophageal adeno carcinoma are needed. The risk locus 
near HTR3C and ABCC5 alone accounts for only a 
fraction of the phenotypic variance; the OR is 1·17 
between patients with oesophageal adenocarcinoma and 
controls, and 1·02 between individuals with Barrett’s 
oesophagus and controls. However, identiﬁ cation of 
further oesophageal adenocarcinoma-speciﬁ c markers 
with larger samples of patients with Barrett’s oesophagus 
and oesophageal adenocarcinoma, together with in-
corporation of relevant environmental and clinical data 
(eg, length of Barrett’s oesophagus segments, presence 
of low-grade dysplasia), and application of modern 
polygenic score approaches will help to identify patients 
with Barrett’s oesophagus at higher risk for oesophageal 
adenocarcinoma. Development of such risk-prediction 
methods would be an important advance in clinical 
management, because this information could be used for 
more eﬀ ective and individualised surveillance and 
intervention strategies. Since genetic data can be used 
for risk prediction at very early stages (eg, before 
development of Barrett’s oesophagus), risk proﬁ ling 
approaches should also focus on markers that contribute 
solely to development of Barrett’s oesophagus and are 
independent of the cause of gastro-oesophageal reﬂ ux.
Pathways analyses showed that cellular processes 
related to muscle-cell diﬀ erentiation and mesenchyme 
development and cell diﬀ erentiation are associated with 
development of Barrett’s oesophagus and oesophageal 
adenocarcinoma. Involvement of the muscle-cell dif-
ferentiation pathway is especially interesting because 
this pathway might represent a link to cellular 
mechanisms in the development of hiatal hernias, which 
have been associated with gastro-oesophageal reﬂ ux and 
Barrett’s oesophagus.36,37 In particular, in the most 
common type 1 hernia, the muscles of the oesophageal 
hiatus are absent or reduced to a few atrophic strands.38 
Thus, muscle-cell diﬀ erentiation pathways could have a 
role in formation of hiatal hernia, which in turn might 
increase the risk for gastro-oesophageal reﬂ ux and 
Barrett’s oesophagus and oesophageal adenocarcinoma. 
By contrast, both mesenchyme-related pathways imply 
that the epithelial-mesenchymal transition plays a part in 
development of Barrett’s oesophagus and oesophageal 
adenocarcinoma, which is characterised by loss of cell 
adhesion and increased cell migration and invasion. 
The epithelial-mesenchymal transition represents an 
essential step in invasion and metastasis of human 
cancers, particularly in early oesophageal adenocarcinoma 
originating from Barrett’s oesophagus.39 However, 
methods used in pathways analyses can diﬀ er between 
studies, and results are not necessarily consistent. Thus, 
although the top pathways in this study are supported by 
the current pathophysiological ideas about Barrett’s 
oesophagus and oesophageal adenocarcinoma, further 
pathways analyses and functional studies could conﬁ rm 
the involvement of these pathways in development of 
Barrett’s oesophagus and oesophageal adenocarcinoma. 
The only locus that showed signiﬁ cant heterogeneity 
between studies was related to SNPs within or near 
TPPP and CEP72. Here, the magnitude of association 
was larger in the Bonn study than in the other studies 
included in our meta-analysis. This ﬁ nding points to a 
so-called winner’s curse eﬀ ect (ie, the phenomenon in 
which the eﬀ ect size of a newly identiﬁ ed genetic 
association is overestimated because of the insuﬃ  cient 
statistical power of the original study) in the Bonn study 
rather than to systematic diﬀ erences between studies, 
because heterogeneity was only noted at this locus.
Our study has several limitations. Although we have 
provided bioinformatics evidence for the functional 
relevance of our ﬁ ndings, we do not provide in-vitro or 
in-vivo evidence for the biological function of these 
ﬁ ndings. Further studies are needed to investigate how 
the identiﬁ ed risk loci contribute to development of 
Barrett’s oesophagus and oesophageal adenocarcinoma 
at the molecular and cellular level. Moreover, our study 
included control individuals who were not screened for 
the presence of Barrett’s oesophagus. Although most 
controls were probably not aﬀ ected by Barrett’s 
oesophagus, inclusion of individuals screened for the 
absence of Barrett’s oesophagus would have increased 
our power to detect further risk loci for Barrett’s 
oesophagus and oesophageal adenocarcinoma. Further-
more, we did not include genome-wide data from a 
suﬃ  ciently high number of patients with isolated 
gastro-oesophageal reﬂ ux. Such data would have 
enabled us to identify risk variants that are predictive 
for the transition from gastro-oesophageal reﬂ ux to 
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Barrett’s oesophagus. Finally, the sample size of our 
study has only power for identiﬁ cation of risk loci with 
moderate eﬀ ects. Although we have used the largest 
available sample of genome-wide association study 
data analysed so far from individuals with Barrett’s 
oesophagus and oesophageal adenocarcinoma, further 
data from additional patients would have led to 
identiﬁ cation of more risk loci.
In conclusion, our meta-analysis identiﬁ ed nine new 
risk loci for Barrett’s oesophagus and oesophageal 
adenocarcinoma and highlighted genes and cellular 
pathways likely to be implicated in disease development. 
To our knowledge, we have identiﬁ ed for the ﬁ rst time 
an oesophageal adenocarcinoma association near the 
HTR3C and ABCC5 genes that is not observed in 
Barrett’s oesophagus. Although the strength of genome-
wide association study meta-analyses is identiﬁ cation of 
disease loci, ﬁ ne-mapping and functional studies 
of new risk loci are now needed to reveal the 
disease pathophysiology. This next step—together with 
identiﬁ cation of additional risk loci using larger sample 
sizes through international collaborative eﬀ orts—should 
lead to identiﬁ cation of key molecules that have an 
important role in development of Barrett’s oesophagus 
and oesophageal adenocarcinoma, which should ﬁ nally 
pave the way for new molecular targets for development 
of advanced prevention and intervention strategies. 
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